Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,021 to 3,040 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: serious adverse events | 37 of 1,209 37 of 1,212 | 0.0 points -1.4 to 1.4 | 2,421 | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
| High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: Incidence of All-cause Mortality | 61 of 1,212 72 of 1,207 | -0.9 points -2.8 to 0.9 | 2,419 | NCT02586155 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
| High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: deaths from any cause | 61 of 1,212 72 of 1,207 | -0.9 points -2.8 to 0.9 | 2,419 | NCT02586155 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
| High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: serious adverse events | 354 of 1,212 339 of 1,207 | 1.1 points -2.5 to 4.7 | 2,419 | NCT02586155 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
| Pimecrolimus vs Topical Corticosteroids: serious adverse events | 247 of 1,205 210 of 1,213 | 3.2 points 0.1 to 6.3 | 2,418 | NCT00120523 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis |
| Unexposed to Gastroenteritis vs Exposed to Gastroenteritis: Number of Participants With Post Infectious Irritable Bowel Syndrome | 23 of 829 114 of 1,586 | -4.4 points -6.1 to -2.6 | 2,415 | NCT00235326 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario |
| Absorb BVS vs XIENCE: Number of Participants With Rehospitalization | 654 of 1,205 621 of 1,210 | 3.0 points -1.0 to 6.9 | 2,415 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Tenofovir Group vs Placebo Group: Number Participants Who Reported More Than One Sexual Partner at Baseline | 251 of 1,204 271 of 1,209 | -1.6 points -4.9 to 1.7 | 2,413 | NCT00119106 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand |
| Tenofovir vs Placebo: Renal Toxicity | 3 of 1,204 3 of 1,209 | 0.0 points -0.5 to 0.5 | 2,413 | NCT00119106 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand |
| Tenofovir vs Placebo: Adverse Events | 1,098 of 1,204 1,083 of 1,209 | 1.6 points -0.7 to 4.0 | 2,413 | NCT00119106 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand |
| Tenofovir vs Placebo: deaths from any cause | 49 of 1,204 58 of 1,209 | -0.7 points -2.4 to 0.9 | 2,413 | NCT00119106 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand |
| Tenofovir vs Placebo: serious adverse events | 227 of 1,204 246 of 1,209 | -1.5 points -4.7 to 1.7 | 2,413 | NCT00119106 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand |
| Tenofovir vs Placebo: Number of Participants Reporting Injecting and Sharing Needles | 58 of 1,204 59 of 1,207 | -0.1 points -1.8 to 1.7 | 2,411 | NCT00119106 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand |
| Palivizumab vs Motavizumab: The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups | 46 of 1,183 24 of 1,227 | 1.9 points 0.6 to 3.3 | 2,410 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Parenteral Nutrition vs Enteral Nutrition: Mortality | 422 of 1,208 443 of 1,202 | -1.9 points -5.7 to 1.9 | 2,410 | NCT01802099 Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines |
| V114 vs Prevnar 13™: deaths from any cause | 1 of 1,972 1 of 437 | -0.2 points -1.2 to 0.1 | 2,409 | NCT03692871 A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) |
| Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Superimposed Preeclampsia | 295 of 1,208 373 of 1,200 | -6.7 points -10.2 to -3.1 | 2,408 | NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project |
| Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Neonatal Hospital Stay of 3 or More Days | 590 of 1,208 592 of 1,200 | -0.5 points -4.5 to 3.5 | 2,408 | NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project |
| Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Hypoglycemia | 191 of 1,208 195 of 1,200 | -0.4 points -3.4 to 2.5 | 2,408 | NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project |
| Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Low Birth Weight | 232 of 1,208 277 of 1,200 | -3.9 points -7.1 to -0.6 | 2,408 | NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project |
Code
curl "https://conductscience.org/api/comparisons/v1?page=152"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=152
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05505734-sae",
"title": "BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: serious adverse events",
"summary": "37 of 1209 against 37 of 1212; risk difference 0.0 points, 95% interval -1.4 to 1.4; NCT05505734, A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma",
"record": "/library/comparisons/NCT05505734-sae",
"nct_id": "NCT05505734",
"kind": "serious-adverse-events",
"participants": 2421,
"risk_difference": {
"value": 0.00007575199207265557,
"lower": -0.013929881750434388,
"upper": 0.01409123103724802
},
"group_1": "37 of 1,209",
"group_2": "37 of 1,212",
"difference": "0.0 points",
"interval": "-1.4 to 1.4",
"trial_title": "A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma"
},
{
"id": "NCT02586155-59a8daa2",
"title": "High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: Incidence of All-cause Mortality",
"summary": "61 of 1212 against 72 of 1207; risk difference -0.9 points, 95% interval -2.8 to 0.9; NCT02586155, Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD",
"record": "/library/comparisons/NCT02586155-59a8daa2",
"nct_id": "NCT02586155",
"kind": "outcome",
"participants": 2419,
"risk_difference": {
"value": -0.009321996822714583,
"lower": -0.027740500883247515,
"upper": 0.008969777700720643
},
"group_1": "61 of 1,212",
"group_2": "72 of 1,207",
"difference": "-0.9 points",
"interval": "-2.8 to 0.9",
"trial_title": "Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=153",
"request_id": "pAfkOc8K1aK-8n0k"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant